Posted by Michael Wonder on 25 Apr 2021
ATAGI reinforce recommendations on use of COVID-19 vaccines following review of vaccine safety data and benefits
23 April 2021 - A statement from the Australian Technical Advisory Group on Immunisation (ATAGI) on use of COVID-19 vaccines following review of vaccine safety data and benefits.
ATAGI is continuing to monitor local and international data on a rare and new condition that occurs after AstraZeneca COVID-19 vaccine called thrombosis with thrombocytopenia syndrome (TTS).
ATAGI has reviewed the additional 3 cases of TTS confirmed by the TGA on 22 April 2021 in Australia, bringing the total confirmed cases to six. Of these cases, 5 people were under 50 years of age. All had received their first dose of AstraZeneca COVID-19 vaccine between 4 and 26 days before the onset of symptoms.
